Cost-utility of sirolimus in the treatment of vascular malformations.

ABSTRACT: Sirolimus is being increasingly employed to manage specific vascular anomalies. We performed an exploratory cost-utility analysis to evaluate sirolimus as a treatment for vascular malformations from the Australian healthcare system perspective. Over a one-year time horizon, sirolimus treatment was associated with an increased expenditure of AU$2832.80 and a gain of 0.08 quality-adjusted life years (QALYs) when compared to supportive care, resulting in an incremental cost-effectiveness ratio of AU$35,410/QALY. By most metrics, sirolimus would be considered a cost-effective treatment for vascular malformations.

SUBMITTER: Li GX 

PROVIDER: S-EPMC11629134 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature